We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Kinnate Biopharma Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 56 → 0 (-56)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $92.2M → $0 (-$92.2M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 56

Holders
–
Holders Change
-56
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
56
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
-$25.7M
2
O
OrbiMed
New York
-$21.3M
3
FCMV
Foresite Capital Management V
California
-$9.38M
4
LCM
Lynx1 Capital Management
Puerto Rico
-$5.27M
5
Viking Global Investors
Viking Global Investors
Connecticut
-$4.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
– -$168K -63,090 Closed
GS
27
GTS Securities
New York
– -$160K -60,038 Closed
Skandinaviska Enskilda Banken (SEB)
28
Skandinaviska Enskilda Banken (SEB)
Sweden
– -$136K -51,200 Closed
SPS
29
Susquehanna Portfolio Strategies
Pennsylvania
– -$129K -48,500 Closed
Jane Street
30
Jane Street
New York
– -$113K -42,378 Closed
JFG
31
Jefferies Financial Group
New York
– -$108K -40,500 Closed
Northern Trust
32
Northern Trust
Illinois
– -$73.9K -27,778 Closed
CAC
33
Cowen and Company
New York
– -$66.5K -25,000 Closed
JP Morgan Chase
34
JP Morgan Chase
New York
– -$65.8K -24,721 Closed
Squarepoint
35
Squarepoint
New York
– -$61.7K -23,187 Closed
Simplex Trading
36
Simplex Trading
Illinois
– -$57K -21,764 Closed
OQS
37
Occudo Quantitative Strategies
Florida
– -$55.7K -20,925 Closed
SG Americas Securities
38
SG Americas Securities
New York
– -$55K -20,819 Closed
BP
39
BBR Partners
New York
– -$53.2K -20,000 Closed
SC
40
Shay Capital
New York
– -$51.6K -19,411 Closed
State Board of Administration of Florida Retirement System
41
State Board of Administration of Florida Retirement System
Florida
– -$89.1K -14,254 Closed
Barclays
42
Barclays
United Kingdom
– -$37.7K -14,185 Closed
PAS
43
Point72 Asia (Singapore)
Singapore
– -$37.5K -14,095 Closed
VF
44
Virtu Financial
New York
– -$30K -11,445 Closed
Mirae Asset Global Investments
45
Mirae Asset Global Investments
South Korea
– -$63.4K -11,200 Closed
Morgan Stanley
46
Morgan Stanley
New York
– -$19.8K -7,427 Closed
Qube Research & Technologies (QRT)
47
Qube Research & Technologies (QRT)
United Kingdom
– -$16.7K -6,262 Closed
CSS
48
Cubist Systematic Strategies
Connecticut
– -$10.9K -4,102 Closed
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
– -$7.8K -2,933 Closed
Bank of America
50
Bank of America
North Carolina
– -$4.79K -1,800 Closed
1
2
3

KNTE Hedge Fund Activity: Q2 2024 in Review

0 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q2 2024, worth a combined $0 — down 100% from $92.2M a quarter earlier.

Sellers outnumbered buyers: 56 funds closed out of KNTE and 0 opened new positions — a net loss of 56 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $25.7M sold.

  • 0 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q2 2024, down from 56 in Q1 2024.
  • Funds reported $0 of Kinnate Biopharma Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q2 2024 and 56 closed out, a net change of -56 holders.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q2 2024 was Foresite Capital Management IV, an estimated $25.7M sold.

Based on aggregated 13F filings for Q2 2024.